降尿酸起始时机 抑制尿酸合成[2,3] 促尿酸排泄
✩ 本文仅供医疗卫生等专业人士参考 1.徐东, 朱小霞, 邹和建, 等 . 痛风诊疗规范 [J]. 中华内科杂志, 2023, 62(9): 1068-1076. 2.中国民族卫生协会重症代谢疾病分会, 中国高尿酸血症相关疾病诊疗多学科专家共识 (2023 年版)[J], 中国实用内科杂志,2023,43(6):461-480 3.中华医学会,痛风基层合理用药指南 [J],中华全科医师杂志,2021,20(6):631-638 4.药物信息,别嘌醇片,北京优华药业有限公司,国药准字 H19993814,《中国药典》2005 版第二部 5.Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016 Feb;81(2):277-89. 6.Vargas-Santos AB, Peloquin CE, Zhang Y, Neogi T. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment. JAMA Intern Med. 2018 Nov 1;178(11):1526-1533. 7.药物信息,非布司他片,江苏万邦生化医药集团有限责任公司,国药准字 H20130058 8.Gao L, Wang B, Pan Y, Lu Y, Cheng R. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis. Clin Cardiol. 2021 Jul;44(7):907-916. 9.Lin TC, Hung LY, Chen YC, Lo WC, Lin CH, Tam KW, Wu MY. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Jul;98(29):e16311. 10.Ziga-Smajic N, Skrbo S, Muratovic S, Pehlivanovic B, Lagumdzija D, Omerovic N. Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients. Med Arch. 2020 Jun;74(3):172-176. 11.药物信息,苯溴马隆片,昆山龙灯瑞迪制药有限公司,国药准字 J20130141 12.Parashar A, Gade SK, Potnuru M, Madhavan N, Manoj KM. The curious case of benzbromarone: insight into super-inhibition of cytochrome P450. PLoS One. 2014 Mar 3;9(3):e89967. |
|
来自: martinbigbird > 《痛风》